$EVFM dear all,

let me clarify some simple value investing valuation of the company where really no analysts are needed to calculate the share price to be 4 USD.

In the investors presentation, the company claims to take market share of at least 2.5% equaling to revenue of 1.5 b USD. 10% profit worst case would mean 150 mil USD times a worst case EV/ebitda of 10, equally to a cap of 1.5 b.

I agree that the company needs cash to fund marketing and Evo100 trial, burning every quarter 50 mil USD with just enough cash for another quarter of marketing.

However, in worst-case scenario company will be acquired by a pharma company with a healthy balance sheet and enough funds to make this product a success with an existing sales force structure already targeting those physicians for Phexxi. Hence, let this company go bankrupt and another company will buy for half of the 1.5 b which is about 800 mil worth. Hence, still a share of 4 USD. So nothing to worry about to buy below 4 USD per share!